Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,352 result(s) found. Displaying page 2,168 of 2,218.
    «« First « Previous 2164  2165  2166  2167  2168  2169  2170  2171  2172  Next» Last»»
    EudraCT Number: 2020-004606-60 Sponsor Protocol Number: BP42772 Start Date*: 2021-06-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS W...
    Medical condition: Advanced or metastatic squamous cell carcinoma of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10015362 Esophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) BE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004476-35 Sponsor Protocol Number: CCFZ533B2201 Start Date*: 2019-08-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 48-week, 6-arm, randomized, double-blind, placebo-controlled multicenter trial to assess the safety and efficacy of multiple CFZ533 doses administered subcutaneously in two distinct populations o...
    Medical condition: Sjögren syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10040767 Sjogren's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) GB (GB - no longer in EU/EEA) NL (Completed) GR (Completed) FR (Completed) DE (Completed) SE (Completed) AT (Completed) SI (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-004130-24 Sponsor Protocol Number: M15-572 Start Date*: 2017-07-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at ...
    Medical condition: Moderately to Severely Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) GR (Completed) NL (Completed) PT (Completed) EE (Completed) LV (Completed) LT (Completed) SI (Completed) HU (Completed) ES (Ongoing) HR (Completed) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001514-41 Sponsor Protocol Number: G040188 Start Date*: 2005-07-06
    Sponsor Name:The Cardiovascular Research Foundation
    Full Title: A dual arm factorial randomized trial in patients with ST segment elevation AMI to compare the results of using either anticoagulation with unfractionated heparin plus routine GP IIb/IIIa inhibitio...
    Medical condition: The medical condition for this clinical trial is Acute Myocardial Infarction (AMI). AMI is defined as death or necrosis of myocardial cells. It is a diagnosis at the end of the spectrum of myocardi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Prematurely Ended) ES (Completed) DE (Completed) GB (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003212-65 Sponsor Protocol Number: ASF-1075-205 Start Date*: 2007-09-05
    Sponsor Name:Astion Pharma A/S
    Full Title: Efficacy and safety of ASF-1075 cream 5% on pruritus in adult patients with atopic dermatitis. A multi-centre, randomised, double-blind, vehicle-controlled, parallel groups, proof of concept study.
    Medical condition: Caucasian male and female patients 18-65 years of age with mild to moderate atopic dermatitis and experiencing moderate to severe pruritus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012438 Dermatitis atopic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000436-25 Sponsor Protocol Number: RC3600 Start Date*: 2012-12-05
    Sponsor Name:Frederiksberg University Hospital
    Full Title: Randomized, double-blinded and placebo-controlled clinical trial of the Rauvolfia-Citrus decoction in patients with type II diabetes
    Medical condition: Non-insulin dependent diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10012637 Diabetes with peripheral circulatory disorders LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045248 Type II diabetes mellitus with other specified manifestations LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045252 Type II diabetes mellitus without mention of complication LLT
    14.1 10027433 - Metabolism and nutrition disorders 10063624 Type II diabetes mellitus inadequate control LLT
    14.1 10027433 - Metabolism and nutrition disorders 10012640 Diabetes with unspecified complications LLT
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-004167-25 Sponsor Protocol Number: NKI-AVLM22TGA Start Date*: 2023-05-04
    Sponsor Name:Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hosp
    Full Title: Phase I/II study with galunisertib combined with capecitabine in patients with advanced chemotherapy resistant colorectal cancer with peritoneal metastases
    Medical condition: Advanced colorectal cancer with peritoneal metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002784-34 Sponsor Protocol Number: NL69665.091.19 Start Date*: 2020-01-08
    Sponsor Name:Radboudumc [...]
    1. Radboudumc
    2. University Medical Center Groningen
    Full Title: Deferoxamine in Aneurysmal Subarachnoid Hemorrhage pilot trial
    Medical condition: patients with aneurysmal subarachnoid hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10007936 Central nervous system aneurysms HLT
    20.1 10029205 - Nervous system disorders 10022758 Intracranial aneurysm PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000794-20 Sponsor Protocol Number: 20160218 Start Date*: 2016-08-30
    Sponsor Name:Radboud University Medical Center
    Full Title: Visualizing beta cells in patients with a history of gestational diabetes
    Medical condition: Gestational diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.0 10036585 - Pregnancy, puerperium and perinatal conditions 10018209 Gestational diabetes PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003324-20 Sponsor Protocol Number: STOPFOP1 Start Date*: 2020-01-08
    Sponsor Name:VU University Medical Center
    Full Title: Saracatinib trial TO Prevent FOP
    Medical condition: Fibrodyplasia Ossificans Progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002372-36 Sponsor Protocol Number: 2022-16039 Start Date*: 2024-01-02
    Sponsor Name:Wageningen Research Stichting
    Full Title: The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo controlled N-of-1 trials
    Medical condition: Insomnia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002145-15 Sponsor Protocol Number: NOK0023 Start Date*: 2023-10-31
    Sponsor Name:Nederlandse Obesitas Kliniek
    Full Title: Applying Mysimba in patients with weight regain after bariatric surgery
    Medical condition: Weight regain post bariatric surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002493-13 Sponsor Protocol Number: M16BRC Start Date*: 2016-09-15
    Sponsor Name:NKI-AVL
    Full Title: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy
    Medical condition: High risk breast cancer (stage III), BRCA1-like
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000070-29 Sponsor Protocol Number: 74668 Start Date*: 2022-09-15
    Sponsor Name:VU University Medical Center
    Full Title: A Proof-of-Concept Study to Explore the Potential Efficacy of Deferiprone in Patients With Pelizaeus-Merzbacher disease (PMD)
    Medical condition: Pelizaeus-Merzbacher disease
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000689-79 Sponsor Protocol Number: 50364 Start Date*: 2015-10-13
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: Rectal preserving treatment for early rectal cancer. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancers.
    Medical condition: Patients with a margin free (at least 1 mm) endoluminal local excision (by TEM, TAMIS, TSPM, EMR/ESD or polypectomy) of an early rectal cancer (below 10 cm). According to current guidelines these ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004588-11 Sponsor Protocol Number: ABR64005 Start Date*: 2019-09-10
    Sponsor Name:University Maastricht
    Full Title: Control Crohn Safe Trial: Long term efficacy and safety of periodic treatment with adalimumab versus standard step-care for newly diagnosed Crohn's disease.
    Medical condition: The chronic inflammatory bowel disease Crohn's disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003012-27 Sponsor Protocol Number: 18062020 Start Date*: 2021-01-12
    Sponsor Name:Canisius Wilhelmina Ziekenhuis
    Full Title: Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy
    Medical condition: Late-onset hypogonadism
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000837-17 Sponsor Protocol Number: NL80854.018.22 Start Date*: 2022-12-07
    Sponsor Name:Amsterdam UMC
    Full Title: Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study
    Medical condition: Inflammatory bowel diseases (Crohn's disease, ulcerative colitis)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005933-34 Sponsor Protocol Number: SFHI01 Start Date*: 2021-08-09
    Sponsor Name:Sorin CRM SAS (Microport CRM)
    Full Title: Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy
    Medical condition: Patients with clinically stable, low to moderate complexity acute Myocardial Infarction (MI; troponine-positive Non-ST-Elevation MI or ST-Elevation MI) requiring primary Percutaneous Coronary Inte...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) NL (Trial now transitioned) ES (Ongoing) IT (Ongoing) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005633-33 Sponsor Protocol Number: 202000842 Start Date*: 2021-06-02
    Sponsor Name:University Medical Center Groningen
    Full Title: Prediction of ECT treatment response and reduction of Cognitive Side-effects using EEG and Rivastigmine
    Medical condition: A depressive disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2164  2165  2166  2167  2168  2169  2170  2171  2172  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 06 08:21:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA